Centanafadine hydrochloride

CAS No. 923981-14-0

Centanafadine hydrochloride( EB-1020 hydrochloride )

Catalog No. M24973 CAS No. 923981-14-0

Centanafadine hydrochloride is a dual inhibitor of norepinephrine (NE)/dopamine (DA) transporter.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 115 In Stock
10MG 192 In Stock
25MG 385 In Stock
50MG 619 In Stock
100MG 972 In Stock
200MG 1305 In Stock
500MG 1944 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Centanafadine hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Centanafadine hydrochloride is a dual inhibitor of norepinephrine (NE)/dopamine (DA) transporter.
  • Description
    Centanafadine hydrochloride is a dual inhibitor of norepinephrine (NE)/dopamine (DA) transporter, also inhibits serotonin transporter (IC50s: 6 nM, 38 nM, and 83 nM for human NE, DA, and serotonin transporter).(In Vitro):Centanafadine (EB-1020) preferentially inhibits monoamine reuptake in cloned cell lines transfected with human transporters with IC50 values of 6 and 38 nM, respectively, for NE and DA transporters, Centanafadine has lesser effects on 5-HT transporter as it inhibits the reuptake of 5-HT with an IC50 value of 83 nM .(In Vivo):In microdialysis studies, Centanafadine markedly increases NE, and DA concentrations levels in rat prefrontal cortex in vivo with peak increases of 375 and 300%, respectively with the greatest effects on NE, and also increases DA extracellular concentrations in the striatum to 400% of baseline concentrations. Behavioral studies demonstrate that Centanafadine dose-dependently decreases immobility in the mouse tail suspension test of depression to 13% of control levels, and do not stimulate locomotor activity in adult rats in the optimal dose range. Centanafadine dose-dependently inhibits locomotor hyperactivity in juvenile rats lesioned with the neurotoxin 6-hydroxydopamine (100 μg intracisternally) as neonates; a well-established animal model for attention-deficit hyperactivity disorder (ADHD).
  • In Vitro
    Centanafadine (EB-1020) preferentially inhibits monoamine reuptake in cloned cell lines transfected with human transporters with IC50 values of 6 and 38 nM, respectively, for NE and DA transporters, Centanafadine has lesser effects on 5-HT transporter as it inhibits the reuptake of 5-HT with an IC50 value of 83 nM .
  • In Vivo
    In microdialysis studies, Centanafadine markedly increases NE, and DA concentrations levels in rat prefrontal cortex in vivo with peak increases of 375 and 300%, respectively with the greatest effects on NE, and also increases DA extracellular concentrations in the striatum to 400% of baseline concentrations. Behavioral studies demonstrate that Centanafadine dose-dependently decreases immobility in the mouse tail suspension test of depression to 13% of control levels, and do not stimulate locomotor activity in adult rats in the optimal dose range. Centanafadine dose-dependently inhibits locomotor hyperactivity in juvenile rats lesioned with the neurotoxin 6-hydroxydopamine (100 μg intracisternally) as neonates; a well-established animal model for attention-deficit hyperactivity disorder (ADHD).
  • Synonyms
    EB-1020 hydrochloride
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    dopamine|Norepinephrine (NE)|serotonin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    923981-14-0
  • Formula Weight
    245.75
  • Molecular Formula
    C15H16ClN
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:125 mg/mL (508.65 mM; Need ultrasonic)
  • SMILES
    [H][C@@]12CNC[C@]1(C3=CC=C4C=CC=CC4=C3)C2.[H]Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bymaster FP, et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse. 2012 Jun;66(6):522-32.
molnova catalog
related products
  • FIIN-2

    FIIN-2, an irreversible, pan-FGFR inhibitor, inhibits FGFR1/2/3/4 with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM, respectively.

  • GSK598809

    GSK598809 (GSK-598809) is a potent, selective, CNS penetrant and orally bioavailable dopamine D3 receptor antagonist with pKi of 8.9; displays >100-fold selectivity over D2 and H1 receptors.

  • Pramipexole dihydroc...

    A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively.